[Malignant hemangioendothelioma of the thyroid gland. Pathology, clinical aspects and prognosis].
Malignant hemangioendothelioma (MHE) of the thyroid still constitutes a relatively important part of our surgical material, with 23 MHE (2.0%) among 1153 primary thyroid tumors diagnosed between 1952 and 1987 (biopsy material of the Innsbruck Pathology Institute). 18 of these cases were investigated immunohistochemically; in 14 cases the data on clinical findings and follow-up were complete. Immunohistochemical results confirm the endothelial origin of this tumor and allow MHE to be definitively distinguished from anaplastic carcinomas. Follow-up and prognosis are determined by the aggressive nature of local tumor spread. 13 patients died after a median survival period of 2.4 months (R: 1.2-9.4). Only one patient has remained alive since over 4 1/2 years now. An improvement of the hitherto dismal prognosis is thought to depend on early tumor diagnosis and an ameliorated combined modality treatment.
Ladurner
D
D
II. Universitätsklinik für Chirurgie, Innsbruck.
Tötsch
M
M
Luze
T
T
Bangerl
I
I
Sandbichler
P
P
Schmid
K W
KW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006390:Hemangioendothelioma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011183:Postoperative Complications / Q000401:mortality*; D015996:Survival Rate; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D013965:Thyroidectomy
D014408:Biomarkers, Tumor
Das maligne Hämangioendotheliom der Schilddrüse. Pathologie, Klinik und Prognose.